Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hydralazine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Psicofarma
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2015
Lead Product(s) : Hydralazine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Psicofarma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydralazine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Momentum Research Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 02, 2013
Lead Product(s) : Hydralazine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Momentum Research Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydralazine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2011
Lead Product(s) : Hydralazine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable